Literature DB >> 16931289

Mast cell mediators in allergic inflammation and mastocytosis.

Mariana Castells1.   

Abstract

Mast cells possess an array of potent inflammatory mediators capable of inducing acute symptoms after cell activation, including urticaria, angioedema, bronchoconstriction, diarrhea, vomiting, hypotension, cardiovascular collapse, and death in few minutes. In contrast, mast cells can provide an array of beneficial mediators in the setting of acute infections, cardiovascular diseases, and cancer. The balance between the detrimental and beneficial roles of mast cells is not completely understood. Although the symptoms of acute mast cell mediator release can be reversed with epinephrine, adrenergic agonists, and mediator blockers, the continued release of histamine, proteases, prostaglandins, leukotrienes, cytokines, and chemokines leads to chronic and debilitating disease, such as mastocytosis. Identification of the molecular factors and mechanisms that control the synthesis and release of mast cell mediators should benefit all patients with mast cell activation syndromes and mastocytosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931289     DOI: 10.1016/j.iac.2006.05.005

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  24 in total

1.  Mercury induces inflammatory mediator release from human mast cells.

Authors:  Duraisamy Kempuraj; Shahrzad Asadi; Bodi Zhang; Akrivi Manola; Jennifer Hogan; Erika Peterson; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2010-03-11       Impact factor: 8.322

2.  The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells.

Authors:  Zuyi Weng; Arti B Patel; Smaro Panagiotidou; Theoharis C Theoharides
Journal:  J Allergy Clin Immunol       Date:  2014-12-10       Impact factor: 10.793

3.  Anaphylaxis and mast cell disease: what is the risk?

Authors:  Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

4.  SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.

Authors:  Alexandra Taracanova; Mihail Alevizos; Anna Karagkouni; Zuiy Weng; Errol Norwitz; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 5.  Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye?

Authors:  Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Shahrzad Asadi; Bodi Zhang; Konstantinos Francis; Magdalini Vasiadi; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Autism Dev Disord       Date:  2011-11

Review 6.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

7.  Neurotensin is increased in serum of young children with autistic disorder.

Authors:  Asimenia Angelidou; Konstantinos Francis; Magdalini Vasiadi; Konstantinos-Dionysios Alysandratos; Bodi Zhang; Athanasios Theoharides; Lefteris Lykouras; Kyriaki Sideri; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2010-08-23       Impact factor: 8.322

Review 8.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

9.  Our perception of the mast cell from Paul Ehrlich to now.

Authors:  Michael A Beaven
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 10.  Anesthetic considerations in pediatric mastocytosis: a review.

Authors:  Norma J Klein; Shad Misseldine
Journal:  J Anesth       Date:  2013-02-14       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.